Grant GrossMendelsohn LLC Lowers Stake in Pfizer Inc. (NYSE:PFE)

Grant GrossMendelsohn LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,802 shares of the biopharmaceutical company’s stock after selling 3,853 shares during the quarter. Grant GrossMendelsohn LLC’s holdings in Pfizer were worth $681,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Front Street Capital Management Inc. increased its stake in shares of Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares in the last quarter. Castleview Partners LLC increased its position in shares of Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares in the last quarter. United Bank increased its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares in the last quarter. Compton Capital Management Inc. RI increased its position in shares of Pfizer by 0.5% during the first quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after acquiring an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. boosted its holdings in Pfizer by 2.4% in the fourth quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Stock Up 0.2 %

Shares of NYSE PFE traded up $0.04 during trading hours on Monday, hitting $25.90. 35,623,531 shares of the stock were exchanged, compared to its average volume of 42,737,133. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market cap of $146.66 billion, a PE ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.61. The firm has a fifty day moving average price of $27.28 and a 200-day moving average price of $28.88. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.33.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the firm earned $1.14 EPS. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.